| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| ACC-006 | ACC-006 | Phase 2 Clinical | China Pharmaceutical University, Jiangsu Aidea Pharmaceutical Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
| Sulforafan alfadex | SFX-01; STP-2 | Phase 2 Clinical | Evgen Pharma, Lalilab, Pharmagra Labs Inc | Asthma; Autism Spectrum Disorder; Autistic Disorder; Breast Neoplasms; Carcinoma in Situ; Drug-Related Side Effects and Adverse Reactions; Head and Neck Neoplasms; Heart Diseases; Heart Failure, Diastolic; Hyperplasia; Kidney Diseases; Lung Neoplasms; Melanoma; Nasolabial fold wrinkles; Neoplasms; Neurodevelopmental Disorders; Parkinson Disease; Precancerous Conditions; Prostatic Neoplasms; Renal Insufficiency, Chronic; Schizophrenia; Squamous Cell Carcinoma of Head and Neck; Subarachnoid Hemorrhage; Ventricular Dysfunction, Left | 詳細 |
| NLM-001 | NLM-001; TAK-441 | Phase 2 Clinical | Millennium Pharmaceuticals Inc | Carcinoma, Basal Cell; Carcinoma, Pancreatic Ductal; Neoplasms | 詳細 |
| IMP5471-CA | Phase 1 Clinical | Shanghai Impact Pharmaceutical Co Ltd | Hematologic Diseases | 詳細 |